Immune Pharmaceuticals Inc (fka IMNPQ)

[Skier1231]

They haven't been able to secure the debtor financing yet, so I'm guessing they wont at this point and just use some of the cash they will receive next week from the Ceplene sale. After they pay the attorneys fees for the Bankruptcy and Rubin his fee, maybe there's a million left. So maybe 8.5- 9 million in liabilities remain.

Then when they sell Bertilimumab, they will probably have to pay a 10% commission to Exterra or whoever puts together the deal. So I would say right now anything over about $10 million from a sale of Bertillimumab would likely go to shareholders. I think its very possible that they could sell just the BP indication rights to whoever they have been in term sheet negotiations with and then if they get positive results from the Ulcerative Colitis trial, they could sell those rights to a different party later- who knows. I also think its likely that whoever buys Bertilimumab will assume alot of the liabilities like Vector did and so wont necessarily have to pay all cash.